AI and predictive analytics are transforming clinical data risk management. CRAs are essential to successful trial. Read more on how tech empowers, not replaces, the CRA. Read the ACT article: https://ow.ly/ESvn50XB6TW
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Pharma giants eye obesity trial boom — but are they ready for what comes next?
ICON survey shows pharma's enthusiasm for multi-indication obesity trials is outpacing trial design readiness.
-
Obesity trial surge puts the focus back on decentralisation
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
Paediatric clinical trials for obesity treatment
In this article, ICON experts Alan Baldridge and Heather Peterson discuss the prevalence of paediatric obesity and assess clinical trials of its treatments.
-
Taking Stock of Obesity Drug Development: Trends and challenges facing today’s researchers
In this article, CON’s Jack Martin discusses the direction obesity drug research is heading, and the challenges faced by researchers.
-
Advancing Research and Development of Multi-indication and Combination Therapies for Obesity
In this article, ICON's Jack Martin explores the impact of comorbidities on obesity therapeutic development including strategic and innovative approaches to therapeutic development and clinical trials design.
-
Overcoming challenges in obesity-related clinical trials
Recent advancements in obesity treatments have spotlighted the field for healthcare providers and developers. In this article from Drug Discovery World, ICON experts share insights on the clinical trials landscape for obesity and why patient centricity is key to overcoming common challenges in the sector.
-
Insight into obesity-related clinical research
In an interview with Contract Pharma, ICON’s Adrienne Stoudenmire and Alan Baldridge discuss current obesity R&D trends, challenges associated with obesity-related clinical research, and opportunities in this sector.
-
The State of Obesity-Related Clinical Research: A Q&A session with ICON's Simon Bruce
ICON’s Simon Bruce, Vice President of Internal Medicine and Drug Development Solutions sits down for a Q&A with Pharmaceutical Executive and gives an overview on the obesity survey carried out by ICON in January 2024 and what it suggests about the state of the obesity-related pipeline.
-
Diabesity: Implications for treatment and drug development
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
ICON survey stresses combo therapies in obesity care
This news piece from The Clinical Trial Vanguard provides an overview of the findings from ICON’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
